Abbott Laboratories Corporation

Abbvie Inc.

Abbott Gmbh & Co Kg

Other

Abbott Gmbh & Cco. Kg

Abbvie Bahamas Limited

David J Calderwood

Gavin C Hirst

Paul Rafferty

Neil Wishart

Lee Daniel Arnold

Kristine E Frank

Kelly Mullen

Michael M Friedman

Andrew Burchat

Kurt Ritter

Heather M Davis

Anna M Ericsson

Michael Michaelides

Maria A Argiriadi

Biqin C Li

Lu Wang

Peter Hrnciar

Nathan Josephsohn

Patrick Betschmann

Steven K Davidsen

Richard W Dixon

Michael L Curtin

Robin R Frey

Michael Z Hoemann

Michael Morytko

Howard Robin Heyman

David Wayne Borhani

Dawn M George

Carol K Wada

Melanie A Muckey

Eric R Goedken

Kent D Stewart

Kevin R Woller

Rainer Munschauer

Eric C Breinlinger

Jeffrey W Voss

David N Johnston

Grier A Wallace

Gagandeep K Somal

Helen L Twigger

Bryan A Fiamengo

Isabel Fernandez

Michael J Morytko

Nathan S Josephsohn

Clara I Villamil

Michael L Friedman

Anil Vasudevan

Thomas D Gordon

Zhiqin Ji

Noel S Wilson

Subhendu Mukherjee

Kevin Patrick Cusack

Michael R Michaelides

Robert V Talanian

Bruce Clapham

Hormoz Mazdiyasni

Dominique Bonafoux

Marina Moran Moset

Jose Maria Castellano Berlanga

Xiaoyun Wu

Ping Ding

Claude E Barberis

Bin Li

Philip Cox

Xiaolei Zhang

Beatriz Gonzalez Pascual

Jose L Ortego Martinez

Maria J Perez De Vega

Steven L Swann

Adelaine Leung

Venkata Srikanth Chitty

Stephen St Gallay

Subramanya Seetharama Shastry Hosahalli

Siva Sanjeeva Rao Thunuguntla

Lily K Abbott

Bojuan B Deng

Gerald B Tometzki

Barbara S Skinner

Eric C Brieinlinger

Andreas Loew

Lu X Wang

David W Borhani

Kelly D Mullen

Biqin Li

Andrew F Burchat

Howard R Heyman

The invention provide a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomer and isomer thereof wherein the variable are defined herein. The compound of the invention are useful for treating immunological and oncological conditions.

Tricyclic compounds

The present invention provides compound of Formula (I) biologically active metabolites, pro-drugs, isomers, stereoisomers, solvates, hydrates and pharmaceutically acceptable salts thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological conditions.

Isoxazolines as therapeutic agents

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

The invention provides a compound of Formula (Ie), 

Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof

The present invention is directed to novel compounds of Formula (I) pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

[object Object]

Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Thienopyridine and furopyridine kinase inhibitors

The present invention is directed to novel compounds of formula (I) wherein the variables are defined as herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

Triazolopyridazines

Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

Indazole compounds

Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disase states where angiogenesis or endothelial cell hyperproliferaton is a factor. These compounds can be used to treat cancer, hyperproliferative disorders, rheumatoid artheritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

4-aminopyrrolopyrimidines as kinase inhibitors

The present application is directed to compounds of the formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.

Substituted 4-amino isoxazolo[5,4-d]pyrimidines as kinase inhibitors

The present invention is directed to novel compounds of formula (I) wherein the variables are as defined herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

Imidazothiazoles and imidazoxazoles

The present invention is directed to novel imidazopyrazine and imidazopyrimidine compounds of formula (I) wherein the variables are as defined herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

Imidazo based heterocycles

The present invention relates to polypeptides which comprise the ligand binding domain of Lck, crystalline forms of these polypeptides, and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Lck. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential selective inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain selectively.

Method of identifying inhibitors of Lck

The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R, R, and Rare defined as described herein.

Pyrazolopyrimidines as therapeutic agents

Growing community of inventors

Framingham, MA, United States of America

David J Calderwood